Maegim한국어

고려제약

014570KOSDAQSector: Pharma & Biotech
₩3,390▲ 1.19%Market cap ₩37.3BAs of Jul 21, 2026 close · updated once daily
A
Grade A71.2 ptsTop 9% of 2,523 stocks
Financial strength
82.8
Growth momentum
21.8
Price attractiveness
93.3

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

82.8
How much debt does it carry relative to equity?
Debt-to-equity ratio
13.5%
✓ Above median · Top 14.8% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
833.0%
✓ Above median · Top 18.1% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
11.1%
✓ Above median · Top 16.3% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
7.8%
✓ Above median · Top 19.7% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

21.8
How much did revenue grow in a year?
Revenue growth (YoY)
-14.4%
✗ Below median · Top 86.1% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
-7.9%
✗ Below median · Top 81.6% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-24.4%
✗ Below median · Top 73.9% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-51.8%
✗ Below median · Top 71.2% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

93.3
Is the price expensive relative to earnings?
P/E (price-to-earnings)
5.7x
✓ Above median · Top 3.9% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.45x
✓ Above median · Top 9.6% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15